Small intestine neuroendocrine tumour
RecruitingStudy on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors
Study on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors
- Disease:Small intestine neuroendocrine tumour
- Substances:Lutetium (177LU) oxodotreotide
Spain- Participants:18–64 years · 65+ years
- Substances:Lutetium (177LU) oxodotreotide
- Sponsor:Grupo Espanol De Tumores Neuroendocrinos









